In addition, VEGFR-tyrosine kinase inhibitor axitinib has been shown to modulate antitumor immunity by downregulating STAT3 expression and reversing the RCC-induced immunosuppression mediated by myeloid-derived suppressor cells [93]. This evidence concerns the gene STAT3 and renal cell carcinoma.